FDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer
May 06, 2020, The U.S. Food and Drug Administration approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Tabrecta is the first FDA-approved therapy to treat NSCLC with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The FDA also approved the FoundationOne CDx assay (F1CDx) as a companion diagnostic for Tabrecta. Most patients had tumor samples that were tested for mutations that lead to MET exon 14 skipping using local tests and confirmed with the F1CDx, which is a next-generation sequencing based in vitro diagnostic device that is capable of detecting several mutations, including mutations that lead to MET exon 14 skipping.
“Lung cancer is increasingly being divided into multiple subsets of molecularly defined populations with drugs being developed to target these specific groups,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “Tabrecta is the first approval specifically for the treatment of patients with non-small cell lung cancer whose tumors have mutations that lead to MET exon 14 skipping. This patient population now has an option for a targeted therapy, which they didn’t have prior to today.”
Common side effects for patients taking Tabrecta are peripheral edema (leg swelling), nausea, fatigue, vomiting, dyspnea (shortness of breath) and decreased appetite.
The FDA granted approval of Tabrecta to Novartis Pharmaceuticals Corporation. The approval of the F1CDx companion diagnostic was granted to Foundation Medicine.
For More Visit:-
- FDA Issues Emergency Use Authorization for Potential COVID 19 Treatment
- Information About Nitrosamine Impurities in Medications
- Important Information About NDMA Impurities in Ranitidine
- Essential Medicines Concept – WHO
Pharma Info Nepal (Nabin’s Blog) is Popular Pharmacy information sharing online platform initiated by Nabin Bist since 2019. Thousands of Pharmacy professionals have trusted Pharma Info Nepal as a right blog to find the latest Pharma opportunities, information & resources for pharmacy updates in Nepal . If you have any complaints, information, or suggestions about the content published on Pharma Info Nepal/If you also like to write an article, please feel free to contact at email@example.com. Thanks for visiting us.
Nepal’s Leading Pharma Portal | Complete Pharma Updates